Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Longevity Medical Institute (LMI) is a regenerative medicine and advanced diagnostics center headquartered in Los Cabos, Mexico. Founded in 2024 by Kirk Sanford, the institute operates a state-of-the-art, federally licensed (COFEPRIS) biotechnology laboratory and a comprehensive medical campus. LMI specializes in physician-directed cellular therapies, including mesenchymal stem cell (MSC) infusions derived from multiple tissue sources, exosome therapy, and NK-cell immunotherapy. The facility integrates cutting-edge diagnostics such as AI-enhanced full-body MRI and extensive biomarker analysis to deliver personalized longevity and anti-aging protocols. LMI is actively involved in clinical research, conducting physician-led studies to validate the efficacy of regenerative treatments for indications such as osteoarthritis, diabetic complications, and cardiovascular health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Longevity Medical Institute.